NX1 — Nexalis Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- AU$4.31m
- AU$4.61m
- AU$0.99m
Annual cashflow statement for Nexalis Therapeutics, fiscal year end - December 31st, AUD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | 0.015 | 0.016 | 0.443 | 0.767 | 0.495 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -1.15 | -1.85 | -1.96 | -0.369 | -0.888 |
| Capital Expenditures | -0.025 | -0 | 0 | — | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | — | — | 0 | 0 |
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.025 | -0 | 0 | 0 | 0 |
| Financing Cash Flow Items | -0.013 | -0.024 | -0.002 | -0.006 | -0.058 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 2.26 | 1.18 | 0.544 | -0.152 | 1.13 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 1.08 | -0.67 | -1.42 | -0.521 | 0.242 |